COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma
Publication date
2023-09-01
Authors
Van Akkooi, Alexander C.J.
Hauschild, Axel
Long, Georgina V.
Mandala, Mario
Kicinski, Michal
Govaerts, Anne Sophie
Klauck, Isabelle
Ouali, Monia
Lorigan, Paul C.
Eggermont, Alexander M.M.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
No license information available
Abstract
Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma.
Keywords
binimetinib, BRAF inhibitor, clinical trial, encorafenib, MEK inhibitor, melanoma, stage IIB, stage IIC, Oncology, Cancer Research
Citation
Van Akkooi, A C J, Hauschild, A, Long, G V, Mandala, M, Kicinski, M, Govaerts, A S, Klauck, I, Ouali, M, Lorigan, P C & Eggermont, A M M 2023, 'COLUMBUS-AD : phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma', Future Oncology, vol. 19, no. 30, pp. 2017-2027. https://doi.org/10.2217/fon-2023-0414